Positive final efficacy results from the phase 3 ORIGIN 3 trial, evaluating Trutakna (atacicept) in adults with primary IgA nephropathy (IgAN) at risk of disease progression. Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, discusses the findings.

 


 

 

Understanding IgA Nephropathy

IgAN is a rare, progressive, immune-mediated kidney disease that affects about 60 out of every 100,000 people in the U.S. The disease causes the antibody, called immunoglobulin A, to build up in the glomeruli of the kidneys, resulting in inflammation and the leakage of red blood cells and protein in the urine. Symptoms may include blood in the urine, persistent low back pain, high blood pressure, and fatigue.

Individuals of all ages can develop IgAN, but it’s often diagnosed in adults between the ages of 30 and 40. Dr. Fordyce shared that for such a young population, the diagnosis can be devastating because it threatens long-term kidney function and increases the risk of irreversible kidney damage or kidney failure. When this happens, dialysis or a kidney transplant is often required, which can significantly affect overall health and quality of life. 

Atacicept, a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor, is a soluble recombinant fusion protein containing the human transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines BAFF and APRIL. BAFF and APRIL are key cytokines that activate B cells and drive IgAN pathophysiology.  

The drug received FDA accelerated approval in July 2026 to reduce proteinuria in adults with primary IgAN at risk of disease progression.

Atacicept Stabilizes Kidney Function in Phase 3 ORIGIN 3 Trial

Positive final efficacy results from the ORIGIN 3 study (NCT04716231) were announced on September 15, 2026 and presented at the American Society of Nephrology (ASN) Kidney Week. They were also published in the New England Journal of Medicine.

ORIGIN 3 was an international, randomized, double-blind, placebo-controlled phase 3 trial evaluating atacicept in adults with primary IgAN at risk of disease progression. The final efficacy analysis included 428 patients. The trial met all prespecified endpoints, demonstrating significant improvements in kidney function compared with placebo through 104 weeks. 

Dr. Fordyce shared that key findings included:

  • Stabilized kidney function

At week 52, mean estimated glomerular filtration rate (eGFR) change from baseline was -0.1 mL/min/1.73 m² among patients receiving atacicept compared with -5.7 among those receiving placebo. 

  • Statistically significant reductions in the hierarchically tested endpoints

Atacicept demonstrated statistically significant reductions in all prespecified measures, including proteinuria, galactose-deficient IgA1 (Gd-IgA1), and hematuria.

  • No patients receiving atacicept required dialysis or kidney transplant

Dr. Fordyce said that in addition to the differences in average kidney function decline, seven patients receiving placebo ended up needing kidney dialysis or a kidney transplant, while none of the patients receiving atacicept required dialysis or a kidney transplant. He shared that these findings were compelling, because they illustrated real clinical outcomes compared to changes in laboratory measurements.

Safety Findings 

Atacicept was well tolerated with a favorable safety profile generally comparable to placebo and consistent with earlier ORIGIN program findings. Overall adverse events and rates of infections and infestations were similar between treatment groups. 

Dr. Fordyce said these findings were especially important given his past experience treating patients with autoimmune diseases. He explained that traditional immunosuppressive therapies, such as high-dose steroids and B-cell-depleting medications, can leave patients vulnerable to infections. Dr. Fordyce said atacicept offers a different approach, giving clinicians another option to treat IgAN without increasing that risk.

Next Steps and Future Research

Vera plans to study atacicept in additional patient populations, including adolescents who were excluded from the original trial and patients with recurrent IgAN following kidney transplantation. Dr. Fordyce explained that patients who receive a transplanted kidney could still lose it if IgAN returns. The company is also investigating atacicept in membranous nephropathy, another kidney disease involving B-cell activity.

Dr. Fordyce then discussed the potential for atacicept to treat other diseases. He shared that even though the current FDA indication only covers adults diagnosed with IgAN who are at risk of disease progression, a growing number of nephrologists are exploring whether it could also be used as a first-line treatment for patients at risk of progressive kidney function loss. 

Additionally, Vera is exploring the potential of atacicept in other conditions involving B-cell activity, including diseases in rheumatology, neurology, and dermatology. 

Vera plans to submit a supplemental biologics license application (sBLA) in the fourth quarter of 2026, with potential full FDA approval in 2027. Dr. Fordyce also said the company expects the final ORIGIN 3 results to undergo FDA review, with a potential label update around the middle of 2027.

In Their Own Words

“What’s exciting is that patients on atacicept were completely normalized with their glomerular filtration rate (GFR). We measure that as an annualized slope; our annualized slope was minus 0.6. The normal decline of kidney function over a lifetime is minus one. So we’re essentially in line with physiologic or normal kidney function over time, which is pretty amazing.” – Marshall Fordyce, MD, founder and CEO of Vera Therapeutics

 

For more information, visit: https://www.globenewswire.com/news-release/2026/09/15/3361855/0/en/vera-therapeutics-announces-trutakna-atacicept-vymj-stabilized-egfr-and-prevented-kidney-disease-progression-through-two-years-in-origin-3-final-efficacy-analysis-in-iga-nephropath.html

For more information on IgAN and other rare kidney and urinary diseases, visit: https://checkrare.com/diseases/kidney-and-urinary-diseases/